1132758-87-2
1132758-87-2
Chemical Structure
Blosozumab
- CAS No.: 1132758-87-2
- Formula:N/A
- Molecular Weight:(144.88 kDa)
IUPAC Name: tert-butyl (6-bromobenzo[d]isoxazol-3-yl)carbamate
SMILES: [Blosozumab]
Biological Activity: Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis[1][2].
| Cat. No. | Nom du produit | Pureté | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Blosozumab | 99.45% | Blosozumab (LY2541546) is an anti-Human sclerostin (SOST) antibody inhibitor. Blosozumab stimulates bone formation and reduces bone resorption. Blosozumab can be used in the research of Osteoporosis. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Robert R Recker, et al. A randomized, double-blind phase 2 clinical trial of blosozumab, a sclerostin antibody, in postmenopausal women with low bone mineral density. J Bone Miner Res. 2015 Feb;30(2):216-24. [Content Brief]
- [2]. Daniel G Rudmann, et al. Rat-specific decreases in platelet count caused by a humanized monoclonal antibody against sclerostin. Toxicol Sci. 2012 Feb;125(2):586-94. [Content Brief]
